CXCL5 and neoplasm: Mechanistically, KIF4A enhances the expression of the chemokine CXCL5, which recruits myeloid-derived suppressor cells (MDSCs) to the tumour microenvironment, thereby inhibiting antitumor immunity, facilitating immune evasion, and promoting tumour growth [9].